Dhansa Labs Ltd
Incorporated in 1985, Ambey Laboratories Ltd is in the business of manufacturing and distribution of agro and home hygiene products.[1]
- Market Cap ₹ 56.1 Cr.
- Current Price ₹ 22.5
- High / Low ₹ 48.3 / 16.2
- Stock P/E 9.80
- Book Value ₹ 39.7
- Dividend Yield 0.00 %
- ROCE 7.99 %
- ROE 6.53 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.57 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 11.6% over past five years.
- Company has a low return on equity of 11.0% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 103 to 139 days.
- Working capital days have increased from 115 days to 169 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of Nifty SME Emerge
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 82 | 85 | 105 | 120 | 131 | 142 | |
| 72 | 74 | 97 | 111 | 122 | 131 | |
| Operating Profit | 10 | 10 | 8 | 9 | 10 | 11 |
| OPM % | 12% | 12% | 7% | 8% | 7% | 8% |
| 1 | 1 | 3 | 1 | 2 | 2 | |
| Interest | 4 | 3 | 2 | 2 | 3 | 3 |
| Depreciation | 3 | 3 | 3 | 2 | 3 | 2 |
| Profit before tax | 3 | 5 | 6 | 6 | 6 | 8 |
| Tax % | -235% | 26% | 5% | -40% | 21% | 25% |
| 10 | 4 | 5 | 8 | 5 | 6 | |
| EPS in Rs | 211.28 | 20.11 | 29.52 | 4.13 | 1.92 | 2.30 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 11% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -11% |
| 3 Years: | 3% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 11% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 5 | 18 | 18 | 19 | 25 | 25 |
| Reserves | -13 | 1 | 1 | 13 | 51 | 74 |
| 33 | 18 | 14 | 30 | 41 | 40 | |
| 20 | 19 | 21 | 18 | 10 | 11 | |
| Total Liabilities | 45 | 56 | 54 | 79 | 127 | 149 |
| 16 | 25 | 25 | 24 | 23 | 21 | |
| CWIP | 1 | 0 | 0 | 4 | 16 | 22 |
| Investments | 0 | 0 | 1 | 1 | 0 | 0 |
| 28 | 31 | 28 | 51 | 88 | 106 | |
| Total Assets | 45 | 56 | 54 | 79 | 127 | 149 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 3 | 6 | 10 | -13 | -34 | -1 | |
| -1 | -1 | -4 | -5 | -14 | -11 | |
| -1 | -5 | -6 | 18 | 48 | 13 | |
| Net Cash Flow | 0 | -0 | 0 | -0 | 0 | 1 |
| Free Cash Flow | 2 | 5 | 7 | -18 | -48 | -7 |
| CFO/OP | 23% | 47% | 120% | -131% | -347% | 0% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 31 | 37 | 12 | 57 | 112 | 139 |
| Inventory Days | 78 | 75 | 99 | 91 | ||
| Days Payable | 74 | 54 | 22 | 18 | ||
| Cash Conversion Cycle | 31 | 37 | 17 | 78 | 189 | 212 |
| Working Capital Days | -10 | 11 | 18 | 49 | 126 | 169 |
| ROCE % | 25% | 22% | 18% | 10% | 8% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtors Turnover Ratio times |
|
||
| Installed Production Capacity: 2,4-D MT |
|||
| Installed Production Capacity: Metribuzin MT |
|||
| Installed Production Capacity: Pretilachlor MT |
|||
| Number of Customers Numbers |
|||
| Total Installed Capacity (Agrochemicals & Intermediates) MT |
|||
| Total Product and Combination Registrations Numbers |
|||
| Cash Conversion Cycle days |
|||
Extracted by Screener AI
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
11 June 2026 - Q4 FY26 earnings call transcript details ₹30 crore Atrazine capex and ₹240 crore CBG/Biofuel plans.
-
Analysts/Institutional Investor Meet/Con. Call Updates
6 June 2026 - Audio recording of 5 June 2026 earnings call for Q4 and FY2025-26 results uploaded.
-
Investor Presentation
5 June 2026 - FY26 audited results: revenue ₹141.54 crore, EBITDA ₹12.22 crore, PAT ₹5.52 crore; expansion and CBG projects outlined.
-
Analysts/Institutional Investor Meet/Con. Call Updates
2 June 2026 - Q4 FY2026 earnings conference call scheduled for 5 June 2026 at 5:00 PM IST.
-
Copy of Newspaper Publication
31 May 2026 - Newspaper advertisement for Q4, half-year and FY2026 standalone/consolidated financial results published on May 31, 2026.
Annual reports
Concalls
-
Jun 2026TranscriptPPTREC
Business Overview:[1][2]
ALL is the 3rd-largest manufacturer of 2,4-D in India. It manufactures
herbicides and home hygiene products, with a high concentration in agrochemicals.
The portfolio currently comprises ~11 agrochemical and ~10 hygiene products,
with 2 additional agrochemical products being introduced. The company has over
200 product and combination registrations. The company has a client base of 250+ customers.